Oncology, Sligo University Hospital, Sligo, Ireland
Oncology, Sligo University Hospital, Sligo, Ireland.
BMJ Case Rep. 2021 May 28;14(5):e243723. doi: 10.1136/bcr-2021-243723.
In recent years, immunotherapy has revolutionised the treatment landscape for oncology patients with improved survival rates in cancers which previously had a dismissal prognosis. These agents target specific pathways of inhibition such as programmed cell death -1 (PD-1), PD ligand-1 and cytotoxic T-lymphocyte-associated antigen 4 resulting in stimulation of T cell activity. This results in enabling an individual's own immune system to fight against cancer, a different modality of treatment when compared with traditional chemotherapy. While attacking the tumour cells, there is an increased chance of host tissue immune reactions.We report a case of a patient who received immunotherapy for metastatic malignant melanoma. During the course of the treatment, development of a sarcoid-like reaction was histologically confirmed in the mediastinal lymph nodes. The patient had no respiratory symptoms and continued on the immunotherapy treatment with good clinical and radiological response.
近年来,免疫疗法彻底改变了肿瘤患者的治疗前景,提高了以往预后不佳的癌症患者的生存率。这些药物针对特定的抑制途径,如程序性细胞死亡蛋白 1(PD-1)、PD 配体-1 和细胞毒性 T 淋巴细胞相关抗原 4,从而刺激 T 细胞活性。这使得个体自身的免疫系统能够对抗癌症,与传统化疗相比是一种不同的治疗模式。在攻击肿瘤细胞的同时,宿主组织免疫反应的机会增加。我们报告了一例接受免疫治疗转移性恶性黑色素瘤的患者。在治疗过程中,纵隔淋巴结的组织学证实发生了类肉瘤样反应。患者无呼吸症状,并继续接受免疫治疗,临床和影像学反应良好。